FdaApplication
NDA 019010
Identifiers
- fda_app_no: NDA019010
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE ENDOCRINE INC |
| application_type | NDA |
| approval_date | 1985-04-09 |
Revenue by product
LUPRON
| Period | Revenue |
|---|---|
| Q4 2021 | $192.0M |
| Q3 2021 | $180.0M |
| Q2 2021 | $198.0M |
| Q1 2021 | $213.0M |
| Q4 2020 | $181.0M |
| Q3 2020 | $133.0M |
| Q2 2020 | $205.0M |
| Q1 2020 | $233.0M |
| Q4 2019 | $219.0M |
| Q3 2019 | $230.0M |
| Q2 2019 | $209.0M |
| Q1 2019 | $229.0M |
| Q4 2018 | $236.0M |
| Q3 2018 | $214.0M |
| Q2 2018 | $223.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LUPRON | LEUPROLIDE ACETATE | 14MG/2.8ML (1MG/0.2ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION;SUBCUTANEOUS |
1 product